retatrutide phase – In a phase III trial led by Eli Lilly, weekly injections of retatrutide for 80 weeks helped overweight or obese participants lose about 30% of body weight on average—roughly 85 pounds—at the highest dose tested. The results place the drug among the most potent
The first thing that stands out in the latest retatrutide trial results isn’t a modest shift—it’s the scale. After 80 weeks of weekly injections. participants in a phase III study run by Eli Lilly lost about 30 percent of their body weight on average. a drop the company describes as roughly 85 pounds.
For many people living with obesity, that number isn’t just impressive. It’s the difference between trying and finally seeing meaningful change. The company says the trial’s weight-loss outcomes bring the next-generation GLP-1 drug one step closer to U.S. Food and Drug Administration approval.
Daniel Drucker. a university professor of medicine at the University of Toronto who previously consulted for Eli Lilly but was not involved in the trial. called retatrutide the most potent GLP-1 medicine he has seen. “This has always been the GLP-1 medicine that we have viewed as the most potent. [with] the greatest weight loss. ” he said. “This has always been the GLP-1 medicine that we have viewed as the most potent. [with] the greatest weight loss. ” he added.
The trial is designed to support the kind of decision regulators make carefully. It is a phase III clinical trial—the gold standard needed to secure eventual FDA approval. Participants were all classified as either overweight or obese, with an average baseline weight of 248.5 pounds.
At the highest doses tested—12 milligrams—participants lost 28.3 percent of their weight on average.
Retatrutide is also different in a way that matters to how it may work. Unlike other approved GLP-1 medications such as Wegovy and Zepbound. which target the gut hormone GLP-1. retatrutide is among a new class aimed at three hormone receptors. It targets GLP-1, glucagon, and glucose-dependent insulinotropic polypeptide (GIP). The logic is straightforward: targeting more than one receptor appears to strengthen weight-loss effects.
Eli Lilly’s results come as other drugs in this family are competing for attention. Tirzepatide, sold under the brand name Zepbound, targets two receptors. Clinical trials suggest tirzepatide helps people lose more weight than semaglutide—the active ingredient in Wegovy—which only targets one.
In the midst of the promise, the trial also put side effects in plain view. About a third of participants reported nausea or diarrhea. Others reported constipation. Between 10 percent and a quarter suffered from vomiting. Drucker said those outcomes are in-line with expectations.
If retatrutide clears regulatory hurdles, he said, it could become the option many people seek when weight loss is hardest. “If it’s approved… this would be the drug that people who need to lose the most amount of weight would gravitate to.”
Kenneth Custer. executive vice president and president of Lilly Cardiometabolic Health. framed the results as evidence of broad potential across obesity stages. “TRIUMPH-1 highlights the importance of options and the potential for retatrutide to help people across various stages of their obesity journey. ” he said in a statement.
retatrutide GLP-1 obesity clinical trial phase III Eli Lilly FDA approval Wegovy Zepbound tirzepatide semaglutide bariatric surgery nausea diarrhea constipation vomiting